Apremilast for children with active juvenile psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 5 and under 18 years old when the study starts
- Your child has a confirmed diagnosis of juvenile psoriatic arthritis for at least 6 months
- Your child currently has active disease, meaning at least 3 active joints
- Your child tried at least one “disease-modifying” arthritis medicine for 2+ months but it didn’t work enough or couldn’t be tolerated
- Your child does not have other types of arthritis or autoimmune disease (like lupus or systemic juvenile idiopathic arthritis)
- Your child does not have certain specific related conditions (like ankylosing spondylitis/uveitis related conditions) and no other inflammatory joint diseases such as gout or rheumatoid arthritis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether apremilast can reduce severe, recurring mouth ulcers compared with an inactive placebo. It aims to improve ulcer frequency and pain while carefully checking safety.
This study tests whether apremilast (a pill) safely and effectively treats moderate-to-severe psoriasis. If you join, you will receive the medication and be monitored by the study team to see how well it works for you.
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
This trial compares two medicines for people with psoriatic arthritis who still have joint, skin, or nail symptoms after methotrexate. One medicine is apremilast (a pill), and the other is adalimumab (an injection). The study aims to see which works better.
Hear when a new Active Juvenile Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.